Mitochondrial Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
• CSF lactate is less suitable as marker of mitochondrial disease.
|
27271921 |
2017 |
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
[<sup>18</sup>F]AV1451-PET cortical SUVR and p-tau showed excellent discrimination between Aβ-positive AD and non-AD conditions (area under the curve 0.92-0.94; ≤0.83 for other CSF measures), and reached 83% classification agreement.
|
29282337 |
2018 |
Alzheimer disease, familial, type 3
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
[<sup>18</sup>F]AV1451-PET cortical SUVR and p-tau showed excellent discrimination between Aβ-positive AD and non-AD conditions (area under the curve 0.92-0.94; ≤0.83 for other CSF measures), and reached 83% classification agreement.
|
29282337 |
2018 |
Abnormal mental state
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Within two clinical trials, we assessed risk factors for altered mental status (GCS score<15) considering baseline clinical characteristics, CSF cytokines/chemokines, and antiretroviral therapy.
|
28329080 |
2017 |
Juvenile Myelomonocytic Leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
With this quantification method, JMML patients with RAS mutations showed significantly higher GM-CSF sensitivity than JMML patients with PTPN11 mutations.
|
18164384 |
2008 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
With the first vaccinia OI (Pexa-Vec, thymidine kinase-inactivated vaccinia expressing Granulocyte-colony stimulating factor [GM-CSF]) now in advanced-stage clinical trials, it has become more important than ever to understand the complimentary MOA that contributes to tumor destruction and control in patients.
|
25900822 |
2015 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99 subjects with AD at the stage of mild cognitive impairment (MCI-AD; n = 25) or at the stage of early dementia (ADD; n = 33), and in nondemented controls (n = 41); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid β (Aβ)1-42, Aβ42/40, Tau, and pTau181), interpreted according to the Erlangen Score algorithm.
|
30055655 |
2018 |
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99 subjects with AD at the stage of mild cognitive impairment (MCI-AD; n = 25) or at the stage of early dementia (ADD; n = 33), and in nondemented controls (n = 41); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid β (Aβ)1-42, Aβ42/40, Tau, and pTau181), interpreted according to the Erlangen Score algorithm.
|
30055655 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99 subjects with AD at the stage of mild cognitive impairment (MCI-AD; n = 25) or at the stage of early dementia (ADD; n = 33), and in nondemented controls (n = 41); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid β (Aβ)1-42, Aβ42/40, Tau, and pTau181), interpreted according to the Erlangen Score algorithm.
|
30055655 |
2018 |
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99 subjects with AD at the stage of mild cognitive impairment (MCI-AD; n = 25) or at the stage of early dementia (ADD; n = 33), and in nondemented controls (n = 41); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid β (Aβ)1-42, Aβ42/40, Tau, and pTau181), interpreted according to the Erlangen Score algorithm.
|
30055655 |
2018 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99 subjects with AD at the stage of mild cognitive impairment (MCI-AD; n = 25) or at the stage of early dementia (ADD; n = 33), and in nondemented controls (n = 41); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid β (Aβ)1-42, Aβ42/40, Tau, and pTau181), interpreted according to the Erlangen Score algorithm.
|
30055655 |
2018 |
Agranulocytosis
|
0.310 |
Biomarker
|
disease |
CTD_human |
With GM-CSF starting on day 1, dose-limiting granulocytopenia occurred during cycle no.
|
8120554 |
1994 |
Invasive Streptococcus pneumoniae disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Why some pneumococci invade the bloodstream or CSF (so-called invasive pneumococcal disease; IPD) is uncertain.
|
30858412 |
2019 |
Recurrent meningitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Whilst recent literature has predominantly centred on CSF leaks and their general investigations and management thereof, there is a paucity of information when it comes to those patients who have persistent post-traumatic CSF leaks, as well as the complication of recurrent meningitis.
|
29807467 |
2018 |
Hydrocephalus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Whilst 80% (50/61) of cases underwent FMD with no preceding or post-operative problems of CSF dynamics, 8% (5/61) of cases had hydrocephalus at initial presentation requiring CSF diversion followed by FMD for persistent Chiari, and 10% (6/61) developed hydrocephalus following FMD and required long-term CSF diversion.
|
31203396 |
2019 |
Thrombocytopenia
|
0.310 |
Biomarker
|
phenotype |
BEFREE |
While the granulocyte colony stimulating factors (G-CSF) filgrastim (Neupogen<sup>®</sup>), pegfilgrastim (Neulasta<sup>®</sup>), and sargramostim (Leukine<sup>®</sup>) are approved to increase survival in patients exposed to a myelosuppressive dose of radiation, no medical countermeasure is currently available for treatment of the thrombocytopenia that also results following radiation exposure.
|
31021662 |
2020 |
Immune thrombocytopenic purpura
|
0.030 |
Biomarker
|
disease |
BEFREE |
While the frequencies of total splenic ILC3 were similar in the two groups, splenic GM-CSF-producing ILC3 were increased in ITP.
|
30055825 |
2018 |
Sinus Thrombosis, Intracranial
|
0.020 |
Biomarker
|
disease |
BEFREE |
While no risk factors were identified, there may be an association between postoperative CVST and CSF leak.
|
30497227 |
2018 |
Cavitation
|
0.010 |
Biomarker
|
disease |
BEFREE |
While lower baseline MD of the RSSI (r<sub>s</sub> = - 0.371; p = 0.004) and more contrast leakage into CSF (r<sub>s</sub> = 0.347; p = 0.007) were associated with the cavitation index in univariable analysis, only BBB leakage in CSF remained independently associated with cavitation (beta = 0.315, p = 0.046).
|
31705427 |
2019 |
Huntington Disease
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
While external validation is required, the attained results are sufficient to conclude tentatively that a clinically relevant alteration of CSF dynamics - that is, one that would justify dose-adjustments of intrathecal drugs - is unlikely to exist in Huntington's disease.
|
30687961 |
2019 |
Creutzfeldt-Jakob disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
While CSF analysis (tau and 14-3-3) and EEG was inconclusive, serial imaging and the clinical course were highly suggestive of CJD.
|
30742601 |
2019 |
Tumor Progression
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
While GM-CSF overexpression and treatment reduced tumor cell proliferation and tumor growth in vitro and in vivo, respectively, it contributed to tumor progression.
|
23634280 |
2013 |
Febrile Neutropenia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Whether and how PP-CSF use may have changed over time (e.g. due to guideline revisions, increasing use of myelosuppressive regimens, controversy regarding inappropriate CSF use), and whether there has been a concomitant change in the incidence of FN, is unknown.
|
30550346 |
2019 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Whereas, CM3D was characterised by a prevailing expression of anti-inflammatory cytokines such as IL-10 and LIF, along with trophic factors involved in different mechanisms leading to tissue regeneration, such as PDGF-BB, FGF-2, I-309, SCF, and GM-CSF; CM2D presented relatively higher levels of IL-6, MCP-1, and IL-21, with recognised pro-inflammatory roles in joint disease and pleiotropic effects in the progression of rheumatoid arthritis (RA).
|
30804924 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
When using the core CSF biomarkers (Aβ42, total Tau and phosphorylated Tau), 30% of the patients fell into the high-AD-likelihood (HL) group (both amyloid and neurodegeneration markers positive), 30% into the low-AD-likelihood group (all biomarkers negative), 28% into the suspected non-Alzheimer pathophysiology (SNAP) group (only neurodegeneration markers positive) and 12% into the isolated amyloid pathology group (only amyloid-positive).
|
29558986 |
2018 |